Abstract: An immunoliposome composition comprised of liposomes bearing a ligand for targeting to cells expressing a growth factor receptor, such as HER2, is described. Binding of the immunoliposome to HER2-expressing cells results in internalization of the immunoliposome for cytoplasmic delivery of an entrapped drug.

Abstract: A liposome composition having a compound entrapped in a supersaturated solution and method for preparing such a composition are described.

Abstract: An amphotericin B composition containing particles of amphotericin B and cholesterol sulfate, in a molar ratio of between about 1:1 to 2:1. The particles, when stored in lyophilized form and reconstituted in an aqueous suspension, have particle sizes predominantly between about 50-250 nm. The composition has stable particle sizes in an aqueous suspension over a several-day storage period. The composition is significantly less toxic and more effective in treating fungal infection than prior amphotericin B formulations.

Abstract: A method of administering a liposome/amphotericin B composition having a predetermined size distribution in 0.2-0.5 micron size range. The method includes preparing a suspension of heterogeneously sized amphotericin B liposomes in an aqueous solution containing at least about 0.5% w/v of membrane-stabilizing agent. After sizing to the desired size distribution, and before the liposome sizes change substantially, the suspension is lyophilized for storage. After reconstituting the lyophilized material, the resulting suspension is administered before a substantial size changes in the liposomes occur.

Abstract: An amphotericin B composition containing particles of amphotericin B and cholesterol sulfate, in a molar ratio of between about 1:1 to 1:4. The particles, when stored in lyophilized form and reconstituted in an aqueous suspension, have particle sizes predominantly between aobut 100-400 nm. The composition formed at a molar ratio of about 1:1 amphotericin B:cholesterol sulfate has stable particle sizes in an aqueous suspension over a several-day storage period. The composition is significantly less toxic and more effective in treating fungal infections than prior amphotericin B formulations.

Abstract: An amphotericin B composition containing particles of amphotericin B and cholesterol sulfate, in a molar ratio of between about 1:1 to 1:4. The particles, when stored in lyophilized form and reconstituted in an aqueous suspension, have particle sizes predominantly between about 100-400 nm. The composition formed at a molar ratio of about 1:1 amphotericin B:cholesterol sulfate ahs stable particle sizes in an aqueous suspension over a several-day storage period. The composition is significantly less toxic and more effective in treating fungal infection than prior amphotericin B formulations.

Abstract: A dehydrated liposome/amphotericin B composition which, upon addition of an aqueous medium, forms a suspension of liposomes (a) having a predetermined size distribution in size range less than about 1 micron, and (b) containing at least about 1 mole percent amphotericin B. The composition is prepared by forming a suspension of heterogeneous size amphotericin B liposomes in an aqueous solution containing at least about 0.5% of a membrane-stabilizing agent. The suspension is sized--for example, by extrusion through a small-pore polycarbonate membrane--to produce liposomes having the selected size distribution, and dehydrated.